Pauwels Eric, Chief Business Officer of PTC Therapeutics (PTCT), has demonstrated a clear selling bias in recent transactions, with no buys and 18 sales recorded since December 2025. The bulk of this activity occurred in a concentrated period, particularly on December 19, 2025, when he executed multiple sales totaling over $2.8 million, including a single transaction valued at $1.32 million coded as a disposition (M). Smaller sales on the same date ranged from $2,799 to $346,309, suggesting a structured liquidation of holdings. The selling momentum continued into early 2026, with transactions on January 6–8 including a $195,712 sale and multiple five-figure disposals, followed by additional sales in mid-February 2026, the largest being $209,398.
Historically, Pauwels has engaged in both buying and selling PTCT shares, with 51 total transactions resulting in $4.94 million in buys and $8.14 million in sells. However, the recent activity skews decisively toward divestment, with no purchases since at least December 2025. The transactions appear methodical, with sales often clustered on single days—December 19 alone accounted for 14 separate filings. While the sales could represent routine portfolio management, the absence of offsetting buys and the scale of disposals—particularly the seven-figure December transactions—highlight a sustained reduction in exposure to PTCT. All activity remains confined to PTC Therapeutics, with no trades in other securities.
AI-assisted summary